Keywords cell death; DJ-1; HtrA2; mitochondria; mutation; neuron; Parkin; Parkinson’s disease; PINK1; signalling Correspondence H.. Loss of protein function result-ing from autosomal-rec
Trang 1Emerging pathways in genetic Parkinson’s disease:
Autosomal-recessive genes in Parkinson’s disease –
a common pathway?
Julia C Fitzgerald and Helene Plun-Favreau
Department of Molecular Neuroscience, Institute of Neurology, University College London, UK
Parkinson’s disease (PD) is a common
neurode-generative disorder with no known cure, estimated to
affect 4 million people worldwide The disease is
char-acterized by the degeneration of dopaminergic neurons
in the substantia nigra pars compacta and the presence
of protein inclusions called Lewy bodies The death of
dopamine neurons in the substantia nigra pars
com-pacta alters neurotransmitter balance in the striatum
resulting in the progressive loss of movement control,
the principal hallmark of PD, encompassing clinical
features such as resting tremor, bradykinesia, postural
instability and rigidity
The most common form of PD is sporadic; there
are, however, inherited forms of PD, accounting for
5–10% of cases Little is known about how or why neurons die in PD, but similarities between both forms
of the disease have led researchers to believe that a common set of molecular mechanisms may underlie
PD aetiology
To date, six genes have been implicated in the pathogenesis of PD, a-synuclein, Parkin, PTEN-induced putative kinase 1 (PINK1), DJ-1, leucine-rich repeat kinase 2 (LRRK2) and ATP13A2 Mutations in the genes encoding a-synuclein, LRRK2 and ATP13A2 cause autosomal-dominant forms of parkinsonism Mutations in the genes encoding Parkin, DJ-1 and PINK1 all cause autosomal-recessive parkinsonism of early onset and are the focus of this minireview
Keywords
cell death; DJ-1; HtrA2; mitochondria;
mutation; neuron; Parkin; Parkinson’s
disease; PINK1; signalling
Correspondence
H Plun-Favreau, Department of Molecular
Neuroscience, Institute of Neurology,
University College London, Queen Square,
London WC1N 3BG, UK
Fax: +44 0207 278 5616
Tel: +44 0207 837 3611; ext 3936
E-mail: h.plun-favreau@ion.ucl.ac.uk
(Received 7 July 2008, revised 9 September
2008, accepted 15 September 2008)
doi:10.1111/j.1742-4658.2008.06708.x
Rare, inherited mutations causing familial forms of Parkinson’s disease have provided insight into the molecular mechanisms that underlie the genetic and sporadic forms of this disease Loss of protein function result-ing from autosomal-recessive mutations in PTEN-induced putative kinase 1 (PINK1), Parkin and DJ-1 has been linked to mitochondrial dysfunction, accumulation of abnormal and misfolded proteins, impaired protein clear-ance and oxidative stress Accumulating evidence suggests that wild-type PINK1, Parkin and DJ-1 may be key components of neuroprotective signalling cascades that run in parallel, interact via cross talk or converge
in a common pathway
Abbreviations
AR-JP, autosomal-recessive juvenile-onset Parkinson’s disease; HtrA2, HtrA serine peptidase 2; LRRK2, leucine-rich repeat kinase 2; PD, Parkinson’s disease; PINK1, PTEN-induced putative kinase 1; PTEN, phosphatase and tensin homologue deleted on chromosome 10; TRAP1, tumour necrosis factor receptor-associated protein 1; UCH-L1, ubiquitin C-terminal hydrolase L1; UPS, ubiquitin proteasomal system.
Trang 2Autosomal-recessive Parkinson’s
disease genes and proteins
Parkin (PARK2)
Mutations in PARK2 were first reported in patients
with autosomal-recessive juvenile-onset PD (AR-JP) [1]
and are now known to be the predominant cause of
early-onset parkinsonism A large number of
patho-genic mutations have been identified in Parkin, present
in 50% of individuals with AR-JP, and 77% of
sporadic cases with disease onset before the age of 20
[2] Clinically, PD patients with mutations in PARK2
suffer a slow progression of the disease commonly
associated with early-onset dystonia and are l-Dopa
responsive [3] Pathological studies on AR-JP patients
with Parkin mutations have revealed a lack of Lewy
body inclusions [4] except in some later onset cases
[5,6]
Parkin localizes predominantly to the cytosol and
cellular vesicles [7–9] However, part of the cellular
Parkin pool associates with the outer mitochondrial
membrane [8] Parkin is an E3 ubiquitin ligase, an
essential component of the ubiquitin-proteasomal
system (UPS) [7] Parkin also has a
proteasome-inde-pendent role and a number of putative substrates for
Parkin have been described, including proteins
impli-cated in PD such as synphilin-1 and a glycosylated
form of a-synuclein [10] It is worth noting, however,
that the only Parkin substrates known to accumulate
in Parkin-null mice are the aminoacyl tRNA synthase
cofactor p38 and far upstream-element binding
protein 1 [11]
PINK1 (PARK6)
Mutations in PARK6 are the second most-common
cause of autosomal-recessive PD after Parkin Initially,
three pedigrees were described with mutations in the
PINK1 gene: a G309D point substitution in one family
and a truncation mutation (W437X) in two additional
families [12] Subsequently, several studies have
described other pathogenic mutations in the PINK1
gene [13] Patients with PINK1 mutations respond well
to l-Dopa treatment but do not have typical AR-JP
phenotype, for example, dystonia at onset [14] The
presence of a mitochondrial targeting sequence first
suggested its precise subcellular location before Gandhi
et al [15] provided evidence that PINK1 is located in
the mitochondrial membranes in human brain tissue
Although a cytoplasmic pool of PINK1 has been
described [16,17] PINK1 is of great interest to
research into mitochondrial dysfunction in PD PINK1
contains a putative catalytic serine–threonine kinase domain and shares homology with calmodulin-depen-dant protein kinase 1 In addition, preliminary evi-dence by Valente et al [12] suggested that PINK1 protected mitochondria and cells against stress
DJ-1 (PARK 7) Mutations in PARK7 are associated with AR-JP and are a rare cause of familial PD [18–20] One reported DJ-1 mutation is a large deletion unlikely to produce any protein The other, a point mutation (L166P), has been studied extensively Later, several studies led to the identification of a number of other pathogenic mutations causing familial PD [21] Clinically, age of onset is usually in the third decade with a slow disease progression and a good response to l-Dopa DJ-1 is localized to both the nucleus and cytoplasm in differ-ent cell types [22,23], although a pool of wild-type DJ-1 has been shown to localize to the mitochondria [24] The L166P mutant protein has been shown to be associated with loss of nuclear localization and trans-location to mitochondria [25] although this was not confirmed in other studies [24] Conversely, localiza-tion of wild-type DJ-1 at the mitochondria is suggested
to be a requirement for neuroprotection [26] DJ-1 has been ascribed various functions, notably in resistance
to oxidative stress [11], but also transcription, cell sig-nalling, apoptosis [27,28] and aggregation of a-synuc-lein [29] The protein may also act as a chaperone Finally, studies suggested that DJ-1 could possess cys-teine protease activity However, the protease activity
of DJ-1 is still a matter of debate [30,31] But perhaps the most important function with regard to PD is its putative role in oxidative stress DJ-1 is thought to protect neurons from oxidative stress [19,32,33] although exactly how it exerts its protective effects remains to be determined
Molecular pathways of neurodegeneration in PD The study of autosomal-recessive PD genes has pro-vided valuable insight into the molecular mechanisms
of dopaminergic degeneration The absence of normal proteins resulting from mutations in these genes causes a range of different but overlapping pathologi-cal effects in neurons, namely mitochondrial impair-ment, proteasomal dysfunction, oxidative stress and protein phosphorylation [34] These processes are being intensively examined, partly in the hope that they will shed light on the more common sporadic form of PD
Trang 3Mitochondrial impairment
Mitochondrial dysfunction has been implicated in the
pathogenesis of a wide range of neurodegenerative
diseases, particularly PD [3] Defects in
mitochon-drial complex I have been closely linked to PD
Environmental toxins causing parkinsonism such as
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and
rote-none inhibit complex I of the mitochondrial electron
transport chain, leading to oxidative stress, impaired
energy metabolism, proteasomal dysfunction and,
eventually, death of dopaminergic neurons [35,36]
Their administration in vivo mimics the pathological
effects of PD [37,38] Interestingly, susceptibility to
rotenone toxicity is increased in neurons from
Parkin-null mice [39] PINK1 suppression using small
interfering RNA decreased cell viability and
signifi-cantly increased 1-methy-4-phenylpyridinium and
rotenone-induced cytotoxicity [40] Furthermore, it has
been reported very recently that germline deletion of
the PINK1 gene in mice significantly impairs
mito-chondrial functions and provides critical protection
against oxidative stress [41,42] Neurons with reduced
levels of endogenous DJ-1 were also sensitized to
toxicity elicited by rotenone [43] and Drosophila DJ-1
mutants were selectively sensitive to environmental
toxins associated with PD [44]
Parkin and PINK1 have been shown to be located,
at least in part, to the mitochondria In Drosophila
models of PINK1, several studies [45–47] strongly
suggested that PINK1 acts upstream of Parkin in a
common pathway that influences mitochondrial
integ-rity in a subset of tissues (including flight muscle and
dopaminergic neurons) Recent studies suggest that
the PINK1⁄ Parkin pathway regulates mitochondrial
morphology in Drosophila and mammalian models
[48–50]
DJ-1 does not seem to operate in the same pathway as
Parkin and PINK1 Muscle and dopaminergic
pheno-types associated with Drosophila PINK1 inactivation
can be suppressed by the overexpression of Parkin, but
not DJ-1 [24] Although there is less evidence for a direct
role of DJ-1 in mitochondrial function, the fact that
Drosophilalacking DJ-1 exhibit increased sensitivity to
environmental mitochondrial toxins [44,51] does point
to a role for DJ-1 in mitochondrial function
Drosophila studies suggest that PINK1 is required
for mitochondrial function and that the PINK1⁄ Parkin
pathway regulates mitochondrial morphology [45–47]
In this connection, a coherent hypothesis is that these
two proteins might act directly at the mitochondrion,
through their respective phosphorylation or
ubiquitina-tion activities Alternatively, PINK1 might need to be
released into the cytosol in order to fulfil its function under conditions of stress This is the case for mito-chondrial proteins such as Smac⁄ Diablo and Omi ⁄ HtrA2 [52] The mature form of these proteins can be generated by proteolysis During apoptosis, mature Omi⁄ HtrA2 and Smac ⁄ Diablo are released from the mitochondria into the cytosol where they exhibit a pro-apoptotic function PINK1 is cleaved [53] and this cleavage seems to play a crucial role in its protective function against various stressors [53,54] However, the protease responsible for PINK1 cleavage as well as the PINK1 cleavage site remains to be identified advances which would shed much light on PINK1s role in the cell It is possible that PINK1 could exhibit an extra-mitochondrial role, interacting with Parkin, DJ-1 and other signalling molecules in the cytosol, which in turn regulate mitochondrial function
Given that mitochondria have crucial roles in multi-ple cellular processes, including metabolism, regulation
of cell cycle and apoptosis, Ca2+ homeostasis, ATP production and cellular signalling, it is likely that Parkin, PINK1, DJ-1 and interactors such as Omi⁄ HtrA2 [55] play a part in these processes
Proteasomal dysfunction and proteolytic stress The proteasome is a large multi-catalytic proteinase complex found in the nucleus and cytoplasm of eukaryotic cells [56,57] UPS dysfunction and proteo-lytic stress are likely to contribute to dopaminergic neurodegeneration [58] Moreover, mutations in two components of the UPS; Parkin and ubiquitin C-termi-nal hydrolase-L1 (UCH-L1) [59] in familial PD strongly supports the hypothesis that proteasomal dysfunction may contribute to PD aetiology [57] Notably knockdown of DJ-1 [60] and Parkin [61,62] enhances susceptibility to proteasome inhibition in cell models In addition, DJ-1-deficient mice treated with the mitochondrial complex I inhibitor paraquat display decreased proteasome activities and increased levels of ubiquitinated protein [63] Finally, the UPS has also been shown to be important for the regulation of PINK1 stability [63] and the degradation of DJ-1 [30,64], PINK1 [65] and Parkin [66,67] mutant proteins
Chaperones may be key players in PD pathogenesis PINK1 has been shown to interact with the Hsp90 molecular chaperone and it was proposed that the inhibition of this interaction might contribute to the pathogenesis of PD [65] Furthermore, PINK1 has been suggested to protect against oxidative stress by phosphorylating the mitochondrial chaperone tumour necrosis factor receptor-associated protein 1 (TRAP1)
Trang 4[68] as well as playing an important role in the
regula-tion of HtrA serine peptidase 2 (HtrA2) protease
activ-ity [55] Moreover, in light of evidence that PINK1
acts upstream of Parkin in the same biological
path-way it is often speculated that PINK1 might
phosphor-ylate Parkin
Structural studies indicate that HtrA2 has
similari-ties to its bacterial homologues DegS and DegP [69]
which function as both molecular chaperones and
pro-teases DJ-1 also has been shown to have similarities
to its stress adaptive homologue Hsp31 [31] suggesting
that both HtrA2 and DJ-1 may degrade unfolded
proteins, performing crucial functions with regard to
protein quality control in different cell compartments
Finally, several chaperones have been shown to be
Parkin substrates [70,71] and Parkin folding seems to
be dependent on chaperones [72]
It is therefore tempting to speculate that proteins
such as Parkin, PINK1, DJ-1, Hsp90, TRAP1 or
HtrA2 might participate in the detoxification of
pro-teins either directly through their putative chaperone
function or indirectly through their interactions with
chaperone molecules
Oxidative stress
Oxidative damage to lipids, proteins and DNA occurs in
PD [73] This stress can directly impair protein
ubiquiti-nation and degradation systems and the toxic products
of oxidative damage induce cell-death mechanisms
Many lines of evidence suggest that DJ-1 functions
as an antioxidant Oxidative stress causes an acidic
shift in the isoelectric point of DJ-1 [26,32,74]
sug-gesting self-oxidation Embryonic stem cells deficient
in DJ-1 display increased sensitivity to oxidative
stress and proteasome inhibition [75] Following
exposure to oxidative stress, DJ-1 associates with
Parkin, potentially linking these proteins into a
com-mon molecular pathway leading to nigral
degenera-tion and PD [76] Parkin knockout mice have
revealed an essential role for Parkin in oxidative
stress [77] and Drosophila Parkin mutants show
increased sensitivity to oxidative stress [78]
Implica-tion of PINK1 in oxidative stress processes has also
been strongly suggested: inactivation of Drosophila
PINK1 using RNAi suggested that PINK1 maintains
neuronal survival by protecting neurons against
oxi-dative stress [79] In mammalian cell culture, PINK1
protects against oxidative stress-induced cell death by
suppressing cytochrome c release from mitochondria,
with the protective action of PINK1 depending on
its ability to phosphorylate the mitochondrial
chaper-one TRAP1 [68]
Protein phosphorylation and signalling pathways PINK1 has a strongly predicted, conserved serine⁄ thre-onine kinase domain [12] and has been shown to exhibit autophosphorylation activity [15,80,81] in vitro
In vivo, PINK1 has been shown to phosphorylate the mitochondrial chaperone TRAP1, protecting against oxidative stress-induced apoptosis [68] and to be important for the phosphorylation of HtrA2 upon activation of the p38 pathway, preventing against mitochondrial stress [55]
PINK1 was originally identified by an analysis of expression profiles from cancer cells after the introduc-tion of exogenous phosphatase and tensin homologue deleted on chromosome 10 (PTEN), a tumour sup-pressor that is involved in the regulation of the phos-phatidylinositol 3-kinase signalling pathway [82] Interestingly, Parkin, DJ-1 and HtrA2, although devoid of kinase activity, have also been shown to be regulated and⁄ or regulators of the phosphatidylinositol 3-kinase pathway A genetic screen of Drosophila gain-of-function mutants has shown that DJ-1 was a nega-tive regulator of PTEN [83], and an impairment of phosphatidylinositol 3-kinase⁄ Akt signalling has been observed in a DJ-1 and Parkin Drosophila model of
PD [51] The phosphatidylinositol 3-kinase⁄ Akt path-way has also been shown to be reduced in Parkin knockout mouse brain [84], suggesting a common molecular event in the pathogenesis of PD In addi-tion, HtrA2 might be directly regulated by Akt [85] Nevertheless, whether the phosphatidylinositol 3-kinase signalling pathway is important for the regulation of Parkin, PINK1, DJ-1 and HtrA2 activity remains to
be determined
Parkin can be phosphorylated by a number of kinases including casein kinase 1, protein kinase A, protein kinase C [86] and cyclin-dependant kinase 5 [87] Phos-phorylation of Parkin by CDK5 may regulate its ubiqu-itin-ligase activity and therefore contribute to the accumulation of toxic Parkin substrates and decreased ability of dopaminergic cells to cope with toxic insults in
PD [87] To date, no direct phosphorylation of DJ-1 or PINK1 has been reported
Conclusion
A common pathway to parkinsonism?
There has been a great deal of interest from the PD scientific community in linking the familial-associated genes in a common pathogenic pathway of neurode-generation To date, however, a single pathway unify-ing these proteins has not been fully mapped out
Trang 5PINK1 and Parkin seem to function, at least in part,
in the same pathway, with PINK1 acting upstream of
Parkin Moreover, a recent study has proposed a role
for Cdc37⁄ Hsp90 chaperones and Parkin on PINK1
subcellular distribution, providing further evidence for a
Parkin⁄ PINK1 common pathogenic pathway in
reces-sive PD [16] The role of the PINK1–Parkin pathway in
regulating mitochondrial function underscores the
importance of mitochondrial impairment as a key
molecular mechanism underlying PD Overexpression
experiments in SH-SY5Y human neuroblastoma cells
have shown that DJ-1 specifically interacts with Parkin
under stress conditions Specifically, this association is
mediated by pathogenic DJ-1 mutations and oxidative
stress [76] These data suggest a link DJ-1 and Parkin in
a common pathway in mammals A described case of
autosomal-recessive PD with digenic inheritance,
suggested that DJ-1 and PINK1 might physically
inter-act and collaborate to protect cells against stress [88]
However, the muscle and dopaminergic phenotypes
associated with Drosophila PINK1 inactivation, can be
rescued by overexpression of Parkin but not DJ-1,
suggest that PINK1 and DJ-1 do not function in the
same pathway, at least in flies [47] Finally, PINK1 has
been shown to interact with HtrA2 and both seem to be
components of the same mitochondrial stress-sensing
pathway [55] Several mutations implicating HtrA2 in
PD have been identified [89] However, the evidence that
mutations in HtrA2 modulate PD risk was later
questioned and continues to be an area of debate
Sanchez et al effectively demonstrated that HtrA2 is
not a PD risk-gene in an extended series of North
Amer-ican PD cases [90] However, Bogaerts et al examined
the contribution of genetic variability in HtrA2 to PD
risk in an extended series of Belgian PD patients and
control individuals This mutational analysis identified a
new mutation (Arg404) strengthening a role for the
HtrA2 mitochondrial protein in PD susceptibility [91]
Each molecular event occurring between genetic
mutation and nigral cell degeneration is intimately
linked to other components of the degenerative
pro-cess The challenge for scientists is therefore to
deter-mine whether there is a single pathway unifying these
proteins or whether the situation is more complicated,
for example, involving cross-talk from other pathways
(Fig 1) If the latter is the case, are there parallel
path-ways leading to the same or similar pathological effects
or are there multiple pathways converging at a
com-mon point? Answering these questions requires a good
PD model Drosophila and more recently zebrafish [92]
models have recapitulated many of the phenotypic and
pathologic features of PD, however, these models are
far-removed from human DA neurons Both primary
neurons and human neuronal cell lines better represent the cell types involved in PD, but have major limita-tions [93] Advances in the field of stem cell research might open up a new route to develop a cell model that more closely mirrors the disease situation in humans The use of induced pluripotent stem cells as a research tool has become very promising following a number of publications showing re-programming of human fibroblasts carrying mutations to induced pluripotent stem cells [94,95] and recently their differ-entiation into specific neuronal subtypes [96]
Understanding the exact function of Parkin, PINK1, DJ-1 and HtrA2 proteins in age-matched healthy volunteer (and ideally relatives) neurons compared with the neurons of patients with AR-JP may allow us to
Fig 1 Protein products of AR-JP genes: Proposed cross-talk of pathways Extracellular and intracellular cues activate universal cell-signalling cascades including MAPK and phosphatidylinositol 3-kinase (PI3K) pathways that can target HtrA2, PINK1, Parkin and DJ-1 Likely these PD-associated proteins are part of a complex network including various signalling pathways Although DJ-1 appears to act slightly more independently than PINK1, Parkin and HtrA2, these PD-associated proteins seem to act in extremely com-plex, multistepped and related pathways The complexity and cross-talk may be important in fine-tuning of cellular responses, allowing points for interjection and feedback There is mounting evidence that these pathways may converge to influence protein folding, protein stability and ultimately mitochondrial function which appear to be central to the mechanism of neuronal cell death
in PD.
Trang 6dissect biochemical pathways that lead to these diseases
and will be a major step forward in our understanding
of the pathogenesis of PD and ultimately to the
development of novel therapeutic approaches
Acknowledgements
The authors wish to thank Professor Nicholas Wood
for his comments
References
1 Kitada T, Asakawa S, Hattori N, Matsumine H,
Yamamura Y, Minoshima S, Yokochi M, Mizuno Y &
Shimizu N (1998) Mutations in the parkin gene cause
autosomal recessive juvenile parkinsonism Nature 392,
605–608
2 Lu¨cking CB, Du¨rr A, Bonifati V, Vaughan J, De
Mic-hele G, Gasser T, Harhangi BS, Meco G, Dene`fle P,
Wood NW et al (2000) Association between early-onset
Parkinson’s disease and mutations in the Parkin gene
N Engl J Med 342, 1560–1567
3 Schapira AH (2008) Mitochondria in the aetiology and
pathogenesis of Parkinson’s disease Lancet Neurol 7,
97–109
4 Hayashi S, Wakabayashi K, Ishikawa A, Nagai H,
Sai-to M, Maruyama M, Takahashi T, Ozawa T, Tsuji S &
Takahashi H (2000) An autopsy case of
autosomal-recessive juvenile parsinsonism with a homozygous
exon 4 deletion in the parkin gene Mov Disord 15, 884–
888
5 Farrer M, Chan P, Chen R, Tan L, Lincoln S,
Hernan-dez D, Forno L, Gwinn-Hardy K, Petrucelli L, Hussey
J et al (2001) Lewy bodies and parkinsonism in families
with parkin mutations Ann Neurol 50, 293–300
6 Pramstaller PP, Schlossmacher MG, Jacques TS,
Scara-velli F, Eskelson C, Pepivani I, Hedrich K, Adel S,
Gonzales-McNeal M, Hilker R et al (2005) Lewy body
Parkinson’s disease in a large pedigree with 77 parkin
mutation carriers Ann Neurol 58, 411–422
7 Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa
S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka
K et al (2000) Familial Parkinson disease gene product,
Parkin, is a ubiquitin-protein ligase Nat Genet 3, 302–
305
8 Darios F, Corti O, Lu¨cking CB, Hampe C, Muriel MP,
Abbas N, Gu WJ, Hirsch EC, Rooney T, Ruberg M
et al.(2003) Parkin prevents mitochondrial swelling and
cytochrome c release in mitochondria-dependent cell
death Hum Mol Genet 12, 517–526
9 Kubo S, Kitami T, Noda S, Shimura H, Uchiyama Y,
Asakawa S, Minoshima S, Shimizu N, Mizuno Y &
Hattori N (2001) Parkin is associated with cellular
vesicles J Neurochem 78, 42–54
10 Wood-Kaczmar A, Gandhi S & Wood NW (2006) Understanding the molecular causes of Parkinson’s disease Trends Mol Med 12, 521–528
11 Doson MW & Guo M (2007) Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson’s disease Curr Opin Neurobiol 17, 331–337
12 Valente EM, Abou-Sleiman PM, Caputo V, Muqit
MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentiv-oglio AR, Healy DG et al (2004) Hereditary early-onset Parkinson’s disease caused by mutations in PINK1 Science 304, 1120–1122
13 Tan E & Skipper LM (2007) Pathogenic mutations in Parkinson’s disease Human Mut 28, 641–653
14 Healey DG, Abou-Sleiman PM & Wood NW (2004) PINK, PANK, or PARK? A clinicians’ guide to familial parkinsonism Lancet Neurol 3, 652–662
15 Gandhi S, Muqit MM, Stanyer L, Healy DG, Abou-Slei-man PM, Hargreaves I, Heales S, Ganguly M, Parsons L, Lees AJ et al (2006) PINK1 protein in normal human brain and Parkinson’s disease Brain 129, 1720–1731
16 Weihofen A, Ostaszewski B, Minami Y & Selkoe DJ (2007) Pink1 Parkinson mutations, the Cdc37⁄ Hsp90 chaperones and Parkin all influence the maturation or subcellular distribution of Pink1 Human Mol Genet 17, 602–616
17 Haque EM, Thomas KJ, D’Souza C, Callaghan S, Kit-ada T, Slack RS, Fraser P, Cookson MR, Tandon A & Park DS (2008) Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP Proc Natl Acad Sci USA 105, 1716–1721
18 Hague S, Rogaeva E, Hernandez D, Gulick C, Single-ton A, Hanson M, Johnson J, Weiser R, Gallardo M, Ravina B et al (2003) Early-onset Parkinson’s disease caused by a compound heterozygous DJ-1 mutation Ann Neurol 54, 271–274
19 Abou-Sleiman PM, Healy DG, Quinn N, Lees AJ & Wood NW (2003) The role of pathogenic DJ-1 muta-tions in Parkinson’s disease Ann Neurol 54, 283–286
20 Hedrich K, Djarmati A, Scha¨fer N, Hering R, Wellen-brock C, Weiss PH, Hilker R, Vieregge P, Ozelius LJ, Heutink P et al (2004) DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease Neurology 62, 389–394
21 Alves da Costa C (2007) DJ-1: a newcomer in Parkin-son’s disease pathology Curr Mol Med 7, 650–657
22 Yoshida K, Sato Y, Yoshike M, Nozawa S, Ariga H & Iwamoto T (2003) Immunocytochemical localisation of DJ-1 in human male reproductive tissue Mol Reprod Dev 66, 391–397
23 Le Naour F, Misek DE, Krause MC, Deneux L, Giord-ano TJ, Scholl S & Hanash SM (2001) Proteomics-based identification of RS⁄ DJ-1 as a novel circulating tumor antigen in breast cancer Clin Cancer Res 7, 3328–3335
Trang 724 Zhang L, Shimoji M, Thomas B, Moore DJ, Yu S,
Marupudi NI, Torp R, Torgner IA, Ottersen OP,
Daw-son TM et al (2005) Mitochondrial localisation of the
Parkinson’s disease related protein DJ-1: implications
for pathogenesis Hum Mol Genet 14, 2063–2073
25 Bonifati V, Rizzu P, van Baren MJ, Schaap O,
Breed-veld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P,
Joosse M et al (2003) Mutations in the DJ-1 gene
asso-ciated with autosomal recessive early-onset
parkinson-ism Science 299, 256–259
26 Canet-Avile´s RM, Wilson MA, Miller DW, Ahmad R,
McLendon C, Bandyopadhyay S, Baptista MJ, Ringe
D, Petsko GA & Cookson MR (2004) The Parkinson’s
disease protein DJ-1 is neuroprotective due to
cysteine-sulfinic acid-driven mitochondrial localization Proc
Natl Acad Sci USA 101, 9103–9108
27 Xu J, Zhong N, Wang H, Elias JE, Kim CY, Woldman
I, Pifl C, Gygi SP, Geula C & Yankner BA (2005) The
Parkinson’s disease-associated DJ-1 protein is a
tran-scriptional co-activator that protects against neuronal
apoptosis Hum Mol Genet 14, 1231–1241
28 Junn E, Taniguchi H, Jeong BS, Zhao X, Ichijo H &
Mouradian MM (2005) Interaction of DJ-1 with Daxx
inhibits apoptosis signal-regulating kinase 1 activity and
cell death Proc Natl Acad Sci USA 102, 9691–9696
29 Shendelman S, Jonason A, Martinat C, Leete T &
Abe-liovich A (2004) DJ-1 is a redox-dependent molecular
chaperone that inhibits alpha-synuclein aggregate
for-mation PLoS Biol 2, e362
30 Olzmann JA, Brown K, Wilkinson KD, Rees HD, Huai
Q, Ke H, Levey AI, Li L & Chin LS (2004) Familial
Parkinson’s disease-associated L166P mutation disrupts
DJ-1 protein folding and function J Biol Chem 279,
8506–8515
31 Lee SJ, Kim SJ, Kim IK, Ko J, Jeong CS, Kim GH,
Park C, Kang SO, Suh PG, Lee HS et al (2003) Crystal
structures of human DJ-1 and Escherichia coli Hsp31,
which share an evolutionarily conserved domain J Biol
Chem 278, 44552–44559
32 Zhou W, Zhu M, Wilson MA, Petsko GA & Fink AL
(2006) The oxidation state of DJ-1 regulates its
chaper-one activity toward alpha-synuclein J Mol Biol 356,
1036–1048
33 Abeliovich A & Flint Beal M (2006) Parkinsonism
genes: culprits and clues J Neurochem 99, 1062–1072
34 Abou-Sleiman PM, Muqit MM & Wood NW (2006)
Expanding insights of mitochondrial dysfunction in
Par-kinson’s disease Nat Rev Neurosci 7, 207–219
35 De Girolamo LA, Billett EE & Hargreaves AJ (2000)
Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
on differentiating mouse N2a neuroblastoma cells
J Neurochem 75, 133–140
36 Caneda-Ferron B, De Girolamo LA, Costa T, Beck
KE, Layfield R & Billett EE (2008) Assessment of the
direct and indirect effects of MPP+and dopamine on
the human proteasome: implications for Parkinson’s disease aetiology J Neurochem 105, 225–238
37 Davis GC, Williams AC, Markey SP, Ebert MH, Caine
ED, Reichert CM & Kopin IJ (1979) Chronic parkin-sonism secondary to intravenous injection of meperidine analogues Psychiat Res 1, 249–254
38 Langston WJ, Ballard P, Tetrus JW & Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis Science 219, 979–980
39 Casarejos MJ, Mene´ndez J, Solano RM, Rodrı´guez-Navarro JA, Garcı´a de Ye´benes J & Mena MA (2006) Susceptibility to rotenone is increased in neurons from Parkin null mice and is reduced by minocycline J Neu-rochem 97, 934–946
40 Deng H, Jankovic J, Guo Y, Xie W & Le W (2005) Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y Biochem Bio-phys Res Commun 337, 1133–1138
41 Gautier CA, Kitada T & Shen J (2008) Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress Proc Natl Acad Sci USA
105, 11364–11369
42 Plun-Favreau H & Hardy J (2008) Pink1 in mitochon-drial function Proc Natl Acad Sci USA 105, 11041– 11042
43 Liu F, Nguyen JL, Hulleman JD, Li L & Rochet JC (2008) Mechanisms of DJ-1 neuroprotection in a cellu-lar model of Parkinson’s disease J Neurochem 105, 2435–2453
44 Meulener M, Whitworth AJ, Armstrong-Gold CE,
Riz-zu P, Heutink P, Wes PD, Pallanck LJ & Bonini NM (2005) Drosophila DJ-1 mutants are selectively sensitive
to environmental toxins associated with Parkinson’s dis-ease Curr Biol 15, 1572–1577
45 Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol
JH, Yoo SJ, Hay BA & Guo M (2006) Drosophila pink1 is required for mitochondrial function and inter-acts genetically with Parkin Nature 441, 1162–1166
46 Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM et al (2006) Mitochondrial dysfunction in Drosophila PINK1 mutants is comple-mented by Parkin Nature 441, 1157–1161
47 Yang Y, Gehrke S, Imai Y, Huang Z, Ouyang Y, Wang
JW, Yang L, Beal MF, Vogel H & Lu B (2006) Mito-chondrial pathology and muscle and dopaminergic neu-ron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin Proc Natl Acad Sci USA
103, 10793–10798
48 Poole AC, Thomas RE, Andrews LA, McBride HM, Whitworth AJ & Pallanck LJ (2008) The PINK1⁄ Par-kin pathway regulates mitochondrial morphology Proc Natl Acad Sci USA 105, 1638–1643
49 Exner N, Treske B, Paquet D, Holmstro¨m K, Schiesling
C, Gispert S, Carballo-Carbajal I, Berg D, Hoepken
HH, Gasser T et al (2007) Loss-of-function of human
Trang 8PINK1 results in mitochondrial pathology and can be
rescued by Parkin J Neurosci 27, 12413–12418
50 Yang Y, Ouyang Y, Yang L, Beal MF, McQuibban
A, Vogel H & Lu B (2008) Pink1 regulates
mitochon-drial dynamics through interaction with the
fis-sion⁄ fusion machinery Proc Natl Acad Sci USA 105,
7070–7075
51 Yang Y, Gehrke S, Haque ME, Imai Y, Kosek J, Yang
L, Beal MF, Nishimura I, Wakamatsu K, Ito S et al
(2005) Inactivation of Drosophila DJ-1 leads to
impair-ments of oxidative stress response and
phosphatidyl-inositol 3-kinase⁄ Akt signaling Proc Natl Acad Sci
USA 102, 13670–13675
52 Ekert PG & Vaux DL (2005) The mitochondrial death
squad: hardened killers or innocent bystanders? Curr
Opin Cell Biol 17, 626–630
53 Muqit MM, Abou-Sleiman PM, Saurin AT, Harvey K,
Gandhi S, Deas E, Eaton S, Payne Smith MD, Venner
K, Matilla A et al (2006) Altered cleavage and
localiza-tion of PINK1 to aggresomes in the presence of
prote-asomal stress J Neurochem 98, 156–169
54 Lin W & Kang UJ (2008) PINK1 characterization of
processing, stability, and subcellular localization J
Neu-rochem 106, 464–474
55 Plun-Favreau H, Klupsch K, Moisoi N, Gandhi S,
Kjaer S, Frith D, Harvey K, Deas E, Harvey RJ,
McDonald N et al (2007) The mitochondrial protease
HtrA2 is regulated by Parkinson’s disease-associated
kinase PINK1 Nat Cell Biol 9, 1243–1252
56 De Martino GN & Slaughter CA (1999) The
protea-some, a novel protease regulated by multiple
mecha-nisms J Biol Chem 274, 22123–22126
57 Tanaka K & Chiba T (1998) The proteasome: a
pro-tein-destroying machine Genes Cells 3, 499–510
58 Dawson TM & Dawson VL (2003) Molecular pathways
of neurodegeneration in Parkinson’s disease Science
302, 819–822
59 Leroy E, Boyer R, Auburger G, Leube B, Ulm G,
Mezey E, Harta G, Brownstein MJ, Jonnalagada S,
Chernova T et al (1998) The ubiquitin pathway in
Parkinson’s disease Nature 395, 451–452
60 Yokota T, Sugawara K, Ito K, Takahashi R, Ariga H
& Mizusawa H (2003) Down regulation of DJ-1
enhances cell death by oxidative stress, ER stress, and
proteasome inhibition Biochem Biophys Res Commun
312, 1342–1348
61 Petrucelli L, O’Farrell C, Lockhart PJ, Baptista M,
Kehoe K, Vink L, Choi P, Wolozin B, Farrer M,
Hardy J et al (2002) Parkin protects against the toxicity
associated with mutant a-synuclein: proteasome
dys-function selectively affects catecholaminergic neurons
Neuron 36, 1007–1019
62 Yang H, Zhou H, Li B, Niu G & Chen S (2007)
Downregulation of Parkin damages antioxidant
defenses and enhances proteasome inhibition-induced
toxicity in PC12 cells J Neuroimmune Pharmacol 2, 276–283
63 Yang W, Chen L, Ding Y, Zhuang X & Kang UJ (2007) Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice Hum Mol Genet 16, 2900–2910
64 Miller DW, Ahmad R, Hague S, Baptista MJ, Canet-Aviles R, McLendon C, Carter DM, Zhu PP, Stadler J, Chandran J et al (2003) L166P mutant DJ-1, causative for recessive Parkinson’s disease, is degraded through the ubiquitin-proteasome system J Biol Chem 278, 36588–36595
65 Moriwaki Y, Kim YJ, Ido Y, Misawa H, Kawashima
K, Endo S & Takahashi R (2008) L347P PINK1 mutant that fails to bind to Hsp90⁄ Cdc37 chaperones is rapidly degraded in a proteasome-dependent manner Neurosci Res 61, 43–48
66 Choi P, Ostrerova-Golts N, Sparkman D, Cochran E, Lee JM & Wolozin B (2000) Parkin is metabolized by the ubiquitin⁄ proteasome system NeuroReport 11, 2635–2638
67 Hyun D, Lee M, Hattori N, Kubo S, Mizuno Y, Halli-well B & Jenner P (2002) Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome J Biol Chem 277, 28572– 28577
68 Pridgeon JW, Olzmann JA, Chin LS & Li L (2008) PINK1 protects against oxidative stress by phosphory-lating mitochondrial chaperone TRAP1 PLoS Biol 5, 1494–1503
69 Young JC & Hartl FU (2003) A stress sensor for the bacterial periplasm Cell 113, 1–2
70 Moore DJ, West AB, Dikeman DA, Dawson VL & Dawson TM (2008) Parkin mediates the degradation-independent ubiquitination of Hsp70 J Neurochem 105, 1806–1819
71 Kahle PJ & Haass C (2004) How does Parkin ligate ubiquitin to Parkinson’s disease? EMBO Rep 5, 681– 685
72 Winklhofer KF, Henn IH, Kay-Jackson PC, Heller U
& Tatzelt J (2003) Inactivation of Parkin by oxidative stress and C-terminal truncations: a protective role
of molecular chaperones J Biol Chem 278, 47199– 47208
73 Anderson JK (2004) Oxidative stress in neurodegenera-tion: cause or consequence? Nat Rev Neurosci 10(Sup-pl.), S18–S25
74 Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi
K & Ariga H (2004) DJ-1 has a role in antioxidative stress to prevent cell death EMBO Rep 5, 213–218
75 Martinat C, Shendelman S, Jonason A, Leete T, Beal
MF, Yang L, Floss T & Abeliovich A (2004) Sensitivity
to oxidative stress in DJ-1-deficient dopamine neurons:
an ES-derived cell model of primary parkinsonism PLoS Biol 2, e327
Trang 976 Moore DJ, Zhang L, Troncoso J, Lee MK, Hattori N,
Mizuno Y, Dawson TM & Dawson VL (2005)
Associa-tion of DJ-1 and Parkin mediated by pathogenic DJ-1
mutations and oxidative stress Hum Mol Genet 14,
71–84
77 Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C,
Wacker M, Klose J & Shen J (2004) Mitochondrial
dys-function and oxidative damage in Parkin-deficient mice
J Biol Chem 279, 18614–18622
78 Pesah Y, Pham T, Burgess H, Middlebrooks B,
Verstre-ken P, Zhou Y, Harding M, Bellen H & Mardon G
(2004) Drosophila Parkin mutants have decreased mass
and cell size and increased sensitivity to oxygen radical
stress Development 131, 2183–2194
79 Wang D, Qian L, Xiong H, Liu J, Neckameyer WS,
Oldham S, Xia K, Wang J, Bodmer R & Zhang Z
(2006) Antioxidants protect PINK1-dependent
dopami-nergic neurons in Drosophila Proc Natl Acad Sci USA
103, 13520–13525
80 Beilina A, Van Der Brug M, Ahmad R, Kesavapany S,
Miller DW, Petsko GA & Cookson MR (2005)
Muta-tions in PTEN-induced putative kinase 1 associated
with recessive Parkinsonism have differential effects on
protein stability Proc Natl Acad Sci USA 102, 5703–
5708
81 Silvestri L, Caputo V, Bellacchio E, Atorino L,
Dalla-piccola B, Valente EM & Casari G (2005)
Mitochon-drial import and enzymatic activity of PINK1 mutants
associated to recessive parkinsonism Hum Mol Genet
14, 3477–3492
82 Unoki M & Nakamura Y (2001) Growth-suppressive
effects of BPOZ and EGR2, two genes involved in
the PTEN signaling pathway Oncogene 20, 4457–
4465
83 Kim RH, Peters M, Jang Y, Shi W, Pintilie M, Fletcher
GC, DeLuca C, Liepa J, Zhou L, Snow B et al (2005)
DJ-1, a novel regulator of the tumor suppressor PTEN
Cancer Cell 7, 263–273
84 Fallon L, Be´langer CM, Corera AT, Kontogiannea M,
Regan-Klapisz E, Moreau F, Voortman J, Haber M,
Rouleau G, Thorarinsdottir T et al (2006) A regulated
interaction with the UIM protein Eps15 implicates
Par-kin in EGF receptor trafficPar-king and PI(3)K-Akt
signal-ling Nat Cell Biol 8, 834–842
85 Yang L, Sun M, Sun XM, Cheng GZ, Nicosia SV &
Cheng JQ (2007) Akt attenuation of the serine protease
activity of HtrA2⁄ Omi through phosphorylation of
serine 212 J Biol Chem 282, 10981–10987
86 Yamamoto A, Friedlein A, Imai Y, Takahashi R,
Kah-le PJ & Haass C (2005) Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity J Biol Chem 280, 3390–3399
87 Avraham E, Rott R, Liani E, Szargel R & Engelender
S (2007) Phosphorylation of Parkin by the cyclin-depen-dent kinase 5 at the linker region modulates its ubiqu-itin-ligase activity and aggregation J Biol Chem 282, 12842–12850
88 Tang B, Xiong H, Sun P, Zhang Y, Wang D, Hu Z, Zhu Z, Ma H, Pan Q, Xia JH et al (2006) Association
of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson’s disease Hum Mol Genet 15, 1816–1825
89 Strauss KM, Martins LM, Plun-Favreau H, Marx FP, Kautzmann S, Berg D, Gasser T, Wszolek Z, Mu¨ller T, Bornemann A et al (2005) Loss of function mutations
in the gene encoding Omi⁄ HtrA2 in Parkinson’s disease Hum Mol Genet 14, 2099–2111
90 Simo´n-Sa´nchez J & Singleton AB (2008) Sequencing analysis of OMI⁄ HTRA2 shows previously reported pathogenic mutations in neurologically normal controls Hum Mol Genet 17, 1988–1993
91 Bogaerts V, Nuytemans K, Reumers J, Pals P, Enge-lborghs S, Pickut B, Corsmit E, Peeters K, Schymko-witz J, De Deyn PP et al (2008) Genetic variability in the mitochondrial serine protease HTRA2 contributes
to risk for Parkinson disease Hum Mutat 29, 832–840
92 Anichtchik O, Diekmann H, Fleming A, Roach A, Goldsmith P & Rubinsztein DC (2008) Loss of Pink1 function affects development and results in neurodegen-eration in zebrafish J Neurosci 28, 8199–8207
93 Falkenburger BH & Schulz JB (2006) Limitations of cellular models in Parkinson’s disease research J Neural Transm 70 (Suppl.), 261–268
94 Hyun-Park I, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K
& Daley GQ (2008) Disease-specific induced pluripotent stem cells Cell 134, 1–10
95 Nishikawa S, Goldstein RA & Nierras CR (2008) The promise of human induced pluripotent stem cells for research and therapy Nat Rev Mol Cell Biol 9, 725–729
96 Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel
R, Goland R et al (2008) Induced pluripotent stem cells generated from patients with ALS can be differen-tiated into notor neurons Science 321, 1218–1221